LA JOLLA, Calif., Sept. 14, 2022 (GLOBE NEWSWIRE) — MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market MNOV and JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875) announced today that they have received an issue notification from the US Patent and Trademark Office for a new patent covering MN-166 (ibudilast) for the treatment of glioblastoma.

This new patent is expected to expire in February 2039 at the earliest. The allowable claims cover a method of treating a patient diagnosed with glioblastoma or recurrent glioblastoma, the patient expressing unmethylated MGMT, using MN-166 (Ibudilast) in combination with one or more other therapeutics including temozolomide (TMZ) , carmustine, bevacizumab, procarbazine, hydroxyurea, irinotecan, lomustine, nimotuzumab, sirolimus, mipsagargin, cabozantinib, onartuzumab, patupilone (epothilone B), and recombinant oncolytic poliovirus (PVS-RIPO). The allowable claims cover a wide range of dosages of MN-166 (Ibudilast) as well as the other therapeutics. The allowable claims also cover different types of glioblastoma including classic glioblastoma, proneural glioblastoma, mesenchymal glioblastoma and neural glioblastoma.

Kazuko Matsuda, MD, PhD, MPH, Chief Medical Officer of MediciNova, Inc., commented, “We are very pleased to be notified of the issuance of this new patent as it compares to our other two patents covering glioblastoma provides additional coverage. We have an ongoing clinical trial of MN-166 in combination with temozolomide for the treatment of recurrent glioblastoma at Harvard Medical School’s Dana-Farber Cancer Institute. The results of our glioblastoma animal model study showed that the median survival time in the group receiving combination treatment with received, MN-166 plus temozolomide was longer compared to the group receiving standard of care temozolomide alone, and these data were published at the American Society of Clinical…